Overcoming the familiar barriers to public learning and understanding of science is focus of new research professorship established by the Hasselblad Foundation jointly at Chalmers University of Technology and Göteborg University in Göteborg, Sweden.
Helping UK universities turn their ideas into business has turned into a business of its own – with four IP management companies quoted on London’s Alternative Investment Market.
It is one thing to recognise the need to manage intellectual property like any other strategic resource. But it is quite another to install the systems and devise the processes for doing it.
If you think it’s hard to do a biotech start up, try doing it in Poland. You’ll face international condescension, local incredulity and the mysteries of Polish law, says Charles Goldfinger.
Everyone wants to encourage innovation. But, says Alain de Serres from the OECD, a survey of the world’s leading industrial countries shows they are going about it in different ways and with very different results.
Not so much a geological specimen as something that will make nanotechnology happen, dendrimers are the young upstarts of the polymer family - but they have promise.
There's nothing light about the scope and ambitions of the University of Manchester's new interdisciplinary Photon Science Institute. The £40 million institute aims to be world-class in pioneering light and laser technologies.
Nanotechnology has the power to transform healthcare. But Europe will lose out to the United States unless it can mount a coherent approach to developing nanomedicine, says a new report.
Scientists at the University of Manchester have invented an electronic nose that can monitor odours and methane at waste landfill and water treatment plants remotely.
Researchers at the University of Bonn in Germany have succeeded in finding a potentially low-cost source of a potent antiviral compound known to prevent replication of the HIV virus in vitro.
Last month the world's leading pharmaceutical company received simultaneous FDA approval for two new therapies. Yet neither drug was invented by the company. Both were originally developed by small biotechs.
TU Delft ditched the usual model of outlicensing or seeking venture capital backing when it was looking to commercialise a novel wastewater treatment technology.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.